These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27371500)

  • 1. Frequency and predictors of bleeding events after 2nd generation drug-eluting stent implantation differ depending on time after implantation.
    Honda Y; Yamawaki M; Mori S; Shirai S; Makino K; Tokuda T; Maruyama T; Takafuji H; Takama T; Tsutumi M; Sakamoto Y; Takimura H; Kobayashi N; Araki M; Hirano K; Sakai T; Ito Y
    J Cardiol; 2017 Apr; 69(4):632-639. PubMed ID: 27371500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation.
    Honda Y; Yamawaki M; Hirano K; Araki M; Kobayashi N; Sakamoto Y; Mori S; Tsutumi M; Takama T; Tokuda T; Makino K; Shirai S; Ito Y
    Heart Vessels; 2017 Nov; 32(11):1285-1295. PubMed ID: 28560486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients.
    Shimizu A; Sonoda S; Muraoka Y; Setoyama K; Inoue K; Miura T; Anai R; Sanuki Y; Miyamoto T; Oginosawa Y; Tsuda Y; Araki M; Otsuji Y
    J Cardiol; 2019 Jun; 73(6):470-478. PubMed ID: 30591321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention.
    Généreux P; Giustino G; Witzenbichler B; Weisz G; Stuckey TD; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri E; Yadav M; Francese DP; Palmerini T; Kirtane AJ; Litherland C; Mehran R; Stone GW
    J Am Coll Cardiol; 2015 Sep; 66(9):1036-45. PubMed ID: 26314532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
    Baber U; Mehran R; Giustino G; Cohen DJ; Henry TD; Sartori S; Ariti C; Litherland C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Kirtane AJ; Stone GW; Colombo A; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S
    J Am Coll Cardiol; 2016 May; 67(19):2224-2234. PubMed ID: 27079334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ultra-long second-generation drug-eluting stent implantation.
    Honda Y; Muramatsu T; Ito Y; Sakai T; Hirano K; Yamawaki M; Araki M; Kobayashi N; Takimura H; Sakamoto Y; Mouri S; Tsutumi M; Takama T; Takafuji H; Tokuda T; Makino K
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):E44-53. PubMed ID: 26010548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
    Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Koskinas KC; Räber L; Zanchin T; Pilgrim T; Stortecky S; Hunziker L; Blöchlinger S; Billinger M; Gartwyl F; Moro C; Moschovitis A; Jüni P; Heg D; Windecker S
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1473-83. PubMed ID: 27478115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
    Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    Lee SW; Park SW; Yun SC; Kim YH; Park DW; Kim WJ; Lee JY; Lee CW; Hong MK; Kim JJ; Park SJ
    Am Heart J; 2010 Feb; 159(2):284-291.e1. PubMed ID: 20152228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES.
    Brodie BR; Garg A; Stuckey TD; Kirtane AJ; Witzenbichler B; Maehara A; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Mehran R; Parvataneni R; Stone GW
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26415600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.